Hugh M. Davis - 03 Feb 2026 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
President and COO, Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
03 Feb 2026
Net transactions value
$0
Form type
4
Filing time
05 Feb 2026, 16:44:00 UTC
Previous filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Hugh M. President and COO, Director C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE /s/ Matthew Rothman, Attorney-in-Fact 05 Feb 2026 0002045027

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +18,675 +70% 45,425 03 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -18,675 -25% $0.000000 56,025 03 Feb 2026 Common Stock 18,675 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.